Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.02
NAS:ICPT's Cash-to-Debt is ranked lower than
72% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. NAS:ICPT: 2.02 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ICPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.02  Med: No Debt Max: No Debt
Current: 2.02
Equity-to-Asset 0.43
NAS:ICPT's Equity-to-Asset is ranked lower than
74% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:ICPT: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ICPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.57 Max: 0.92
Current: 0.43
-0.13
0.92
Piotroski F-Score: 3
Altman Z-Score: 1.54
Beneish M-Score: 3.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1613.38
NAS:ICPT's Operating Margin % is ranked lower than
82% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. NAS:ICPT: -1613.38 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ICPT' s Operating Margin % Range Over the Past 10 Years
Min: -8237.1  Med: -2022.81 Max: -766.2
Current: -1613.38
-8237.1
-766.2
Net Margin % -1654.63
NAS:ICPT's Net Margin % is ranked lower than
82% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. NAS:ICPT: -1654.63 )
Ranked among companies with meaningful Net Margin % only.
NAS:ICPT' s Net Margin % Range Over the Past 10 Years
Min: -16258.67  Med: -2981.9 Max: -705.71
Current: -1654.63
-16258.67
-705.71
ROE % -92.27
NAS:ICPT's ROE % is ranked lower than
76% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. NAS:ICPT: -92.27 )
Ranked among companies with meaningful ROE % only.
NAS:ICPT' s ROE % Range Over the Past 10 Years
Min: -180.8  Med: -91.41 Max: -54.36
Current: -92.27
-180.8
-54.36
ROA % -62.08
NAS:ICPT's ROA % is ranked lower than
71% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. NAS:ICPT: -62.08 )
Ranked among companies with meaningful ROA % only.
NAS:ICPT' s ROA % Range Over the Past 10 Years
Min: -140.05  Med: -62.75 Max: -49.77
Current: -62.08
-140.05
-49.77
ROC (Joel Greenblatt) % -3479.19
NAS:ICPT's ROC (Joel Greenblatt) % is ranked lower than
76% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. NAS:ICPT: -3479.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ICPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8893.89  Med: -5930.8 Max: -2848.34
Current: -3479.19
-8893.89
-2848.34
3-Year Revenue Growth Rate 124.00
NAS:ICPT's 3-Year Revenue Growth Rate is ranked higher than
95% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:ICPT: 124.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ICPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -39.65 Max: 124
Current: 124
0
124
3-Year EBITDA Growth Rate 94.30
NAS:ICPT's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:ICPT: 94.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ICPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 48.55 Max: 94.3
Current: 94.3
-22.9
94.3
3-Year EPS without NRI Growth Rate 64.50
NAS:ICPT's 3-Year EPS without NRI Growth Rate is ranked higher than
93% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:ICPT: 64.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ICPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -11.4  Med: 25.7 Max: 64.5
Current: 64.5
-11.4
64.5
GuruFocus has detected 4 Warning Signs with Intercept Pharmaceuticals Inc $NAS:ICPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ICPT's 10-Y Financials

Financials (Next Earnings Date: 2017-05-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ICPT Guru Trades in Q1 2016

Steven Cohen 10,300 sh (New)
Columbia Wanger 187,043 sh (+0.09%)
George Soros Sold Out
» More
Q2 2016

ICPT Guru Trades in Q2 2016

George Soros 8,100 sh (New)
Columbia Wanger 233,573 sh (+24.88%)
Steven Cohen Sold Out
» More
Q3 2016

ICPT Guru Trades in Q3 2016

Columbia Wanger 192,510 sh (-17.58%)
George Soros 3,623 sh (-55.27%)
» More
Q4 2016

ICPT Guru Trades in Q4 2016

Steven Cohen 195,100 sh (New)
George Soros Sold Out
Columbia Wanger Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ICPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CLVS, NAS:CBPO, OTCPK:BTGGF, NAS:RARE, NAS:SAGE, NYSE:XON, NAS:BLUE, NAS:JUNO, NAS:GLPG, NAS:NKTR, NAS:AVXS, NAS:TECH, NAS:LGND, NAS:AGIO, NAS:PTLA, OTCPK:ABCZY, NAS:PRTA, NAS:HALO, NAS:ONCE, NAS:ARRY » details
Traded in other countries:I4P.Germany,
Intercept Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry.

Intercept is a biotech company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva for the treatment of primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of Japan, China, and Korea, where it has licensed out the product to Sumitomo Dainippon Pharma.

Ratios

vs
industry
vs
history
PB Ratio 9.12
ICPT's PB Ratio is ranked lower than
84% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ICPT: 9.12 )
Ranked among companies with meaningful PB Ratio only.
ICPT' s PB Ratio Range Over the Past 10 Years
Min: 3.99  Med: 9.29 Max: 104.9
Current: 9.12
3.99
104.9
PS Ratio 114.67
ICPT's PS Ratio is ranked lower than
84% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. ICPT: 114.67 )
Ranked among companies with meaningful PS Ratio only.
ICPT' s PS Ratio Range Over the Past 10 Years
Min: 42.02  Med: 1286.45 Max: 5193.93
Current: 114.67
42.02
5193.93
Current Ratio 9.02
ICPT's Current Ratio is ranked higher than
76% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ICPT: 9.02 )
Ranked among companies with meaningful Current Ratio only.
ICPT' s Current Ratio Range Over the Past 10 Years
Min: 4.69  Med: 11.29 Max: 16.62
Current: 9.02
4.69
16.62
Quick Ratio 9.02
ICPT's Quick Ratio is ranked higher than
77% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ICPT: 9.02 )
Ranked among companies with meaningful Quick Ratio only.
ICPT' s Quick Ratio Range Over the Past 10 Years
Min: 4.69  Med: 11.29 Max: 16.62
Current: 9.02
4.69
16.62
Days Sales Outstanding 133.51
ICPT's Days Sales Outstanding is ranked lower than
81% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. ICPT: 133.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
ICPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 80.28  Med: 131.16 Max: 535.77
Current: 133.51
80.28
535.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.60
ICPT's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ICPT: -8.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ICPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -86  Med: -46.85 Max: -8.6
Current: -8.6
-86
-8.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.92
ICPT's Price-to-Net-Cash is ranked lower than
71% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. ICPT: 10.92 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ICPT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.34  Med: 10.17 Max: 17.2
Current: 10.92
6.34
17.2
Price-to-Net-Current-Asset-Value 10.21
ICPT's Price-to-Net-Current-Asset-Value is ranked lower than
73% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. ICPT: 10.21 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ICPT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.19  Med: 9.51 Max: 16.61
Current: 10.21
6.19
16.61
Price-to-Tangible-Book 9.19
ICPT's Price-to-Tangible-Book is ranked lower than
78% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ICPT: 9.19 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ICPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.05  Med: 8.59 Max: 16.07
Current: 9.19
6.05
16.07
Price-to-Median-PS-Value 0.09
ICPT's Price-to-Median-PS-Value is ranked higher than
98% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ICPT: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ICPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.58 Max: 1.46
Current: 0.09
0.04
1.46
Earnings Yield (Greenblatt) % -15.83
ICPT's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. ICPT: -15.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ICPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3511.09  Med: 0 Max: 0
Current: -15.83
-3511.09
0

More Statistics

Revenue (TTM) (Mil) $24.95
EPS (TTM) $ -16.74
Beta1.98
Short Percentage of Float57.71%
52-Week Range $96.63 - 177.93
Shares Outstanding (Mil)24.83

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 105 259 504
EPS ($) -16.02 -12.30 -5.28
EPS without NRI ($) -16.02 -12.30 -5.28
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ICPT

Headlines

Articles On GuruFocus.com
Intercept Pharmaceuticals Inc (ICPT) Moves Forward With OCA REGENERATE Trial; Buy Why Did Shares Sli May 20 2015 
Analysts are Positive on Intercept Pharmaceuticals Inc Following Quarterly Earnings and Pipeline Upd May 12 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST Mar 30 2015 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc, Ross Stores Inc, Sally Beauty Holdings In Mar 30 2015 
Intercept Pharmaceuticals Announces Two New Sub-Groups for FLINT Trial Mar 24 2015 
Intercept Pharma’s Losses Widen, but Revenue Rises Mar 03 2015 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Intercept Pharmaceuticals (ICPT) Obeticholic Acid Momentum, Gigamon (GIMO) Robust Revenue Growth Jan 30 2015 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 

More From Other Websites
Intercept to Present at Upcoming Conference Mar 16 2017
INTERCEPT PHARMACEUTICALS INC Financials Mar 07 2017
Morningstar Runs the Numbers Mar 04 2017
Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales... Mar 03 2017
NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary... Mar 02 2017
INTERCEPT PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 01 2017
Intercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017 Feb 27 2017
Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat Feb 24 2017
Nasdaq Slips as Biotechnology Shares Decline Feb 24 2017
Nasdaq Slips as Biotechnology Shares Decline Feb 23 2017
Edited Transcript of ICPT earnings conference call or presentation 23-Feb-17 1:30pm GMT Feb 23 2017
Intercept (ICPT) Reports a Wider Q4 Loss Feb 23 2017
Intercept reports 4Q loss Feb 23 2017
Intercept reports 4Q loss Feb 23 2017
INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 23 2017
Q4 2016 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open Feb 23 2017
Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update Feb 23 2017
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More Feb 22 2017
Intercept (ICPT) to Post Q4 Earnings: What's in the Cards? Feb 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)